Tower Bridge Advisors Position in Expedia Del (EXPE) Raised by $201.52 Million; Immunomedics (Call) (IMMU) Shares Rose While Venbio Select Advisor Lowered Position

January 17, 2018 - By Maria Brooks

Tower Bridge Advisors increased its stake in Expedia Inc Del (EXPE) by 2.43% based on its latest 2017Q3 regulatory filing with the SEC. Tower Bridge Advisors bought 1,400 shares as the company’s stock rose 18.57% with the market. The institutional investor held 59,122 shares of the consumer services company at the end of 2017Q3, valued at $8.51 billion, up from 57,722 at the end of the previous reported quarter. Tower Bridge Advisors who had been investing in Expedia Inc Del for a number of months, seems to be bullish on the $19.94 billion market cap company. The stock increased 0.11% or $0.14 during the last trading session, reaching $130.74. About 980,442 shares traded. Expedia, Inc. (NASDAQ:EXPE) has risen 30.43% since January 17, 2017 and is uptrending. It has outperformed by 13.73% the S&P500.

Venbio Select Advisor Llc decreased its stake in Immunomedics Inc (Call) (IMMU) by 91.66% based on its latest 2017Q3 regulatory filing with the SEC. Venbio Select Advisor Llc sold 9.61M shares as the company’s stock rose 37.64% with the market. The institutional investor held 875,000 shares of the health care company at the end of 2017Q3, valued at $6.30M, down from 10.49M at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Immunomedics Inc (Call) for a number of months, seems to be less bullish one the $2.58B market cap company. The stock increased 3.88% or $0.6 during the last trading session, reaching $16.07. About 1.53M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since January 17, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Investors sentiment increased to 1.43 in Q3 2017. Its up 0.14, from 1.29 in 2017Q2. It increased, as 42 investors sold EXPE shares while 152 reduced holdings. 84 funds opened positions while 193 raised stakes. 124.65 million shares or 0.14% more from 124.48 million shares in 2017Q2 were reported. Teacher Retirement Of Texas stated it has 0.04% in Expedia, Inc. (NASDAQ:EXPE). Ameritas Partners owns 5,235 shares. Alta Cap Mngmt Lc, Utah-based fund reported 1,724 shares. Loring Wolcott And Coolidge Fiduciary Advsr Llp Ma has invested 0% of its portfolio in Expedia, Inc. (NASDAQ:EXPE). Huntington Bancorp has invested 0% in Expedia, Inc. (NASDAQ:EXPE). Eqis Cap Mngmt reported 0.03% in Expedia, Inc. (NASDAQ:EXPE). Arrowstreet Partnership holds 282,886 shares. Symphony Asset Management Ltd Liability invested in 2,571 shares or 0.04% of the stock. Hudson Bay Cap Mngmt Ltd Partnership holds 21,500 shares or 0.08% of its portfolio. Cornerstone Holding Ltd Limited Liability Company has invested 0.3% in Expedia, Inc. (NASDAQ:EXPE). Cornerstone Advsr Inc has invested 0.04% of its portfolio in Expedia, Inc. (NASDAQ:EXPE). 773 were accumulated by San Francisco Sentry Inv Gp (Ca). Retirement Of Alabama reported 0.04% stake. Piedmont Advisors Limited Liability Co owns 5,983 shares. Nelson Roberts Advsr Limited Com holds 60 shares.

Tower Bridge Advisors, which manages about $1.11 billion and $879.96B US Long portfolio, decreased its stake in Johnson Controls Intl by 835 shares to 14,534 shares, valued at $585.58 million in 2017Q3, according to the filing. It also reduced its holding in Metlife Inc Pfd A Flt by 2,525 shares in the quarter, leaving it with 118,974 shares, and cut its stake in Unilever N V (NYSE:UN).

Among 36 analysts covering Expedia Inc. (NASDAQ:EXPE), 27 have Buy rating, 0 Sell and 9 Hold. Therefore 75% are positive. Expedia Inc. had 106 analyst reports since July 24, 2015 according to SRatingsIntel. Deutsche Bank maintained Expedia, Inc. (NASDAQ:EXPE) on Tuesday, October 24 with “Buy” rating. Piper Jaffray maintained the shares of EXPE in report on Tuesday, July 11 with “Buy” rating. The firm has “Buy” rating given on Friday, July 7 by Cowen & Co. Oppenheimer upgraded it to “Outperform” rating and $157 target in Thursday, November 5 report. Nomura maintained the stock with “Neutral” rating in Thursday, February 11 report. Morgan Stanley upgraded the stock to “Buy” rating in Wednesday, January 10 report. The rating was maintained by UBS on Friday, September 22 with “Buy”. Jefferies upgraded the stock to “Buy” rating in Friday, August 25 report. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, February 11. On Monday, July 27 the stock rating was maintained by Benchmark with “Buy”.

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Wednesday, December 6. The rating was maintained by Cowen & Co with “Buy” on Wednesday, December 6. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Thursday, October 6 by Jefferies. Jefferies maintained it with “Hold” rating and $1.50 target in Tuesday, March 15 report. The company was downgraded on Friday, December 4 by Wells Fargo. Jefferies downgraded Immunomedics, Inc. (NASDAQ:IMMU) rating on Wednesday, July 29. Jefferies has “Hold” rating and $2 target. As per Wednesday, August 16, the company rating was maintained by Cowen & Co. Jefferies maintained the shares of IMMU in report on Monday, October 9 with “Buy” rating. The firm has “Buy” rating given on Friday, June 9 by Jefferies. On Friday, May 6 the stock rating was upgraded by Jefferies to “Buy”.

Since August 21, 2017, it had 0 insider purchases, and 6 selling transactions for $2.10 million activity. 20,000 shares were sold by GOLDENBERG DAVID M, worth $252,750 on Thursday, August 31.

Investors sentiment increased to 1.65 in 2017 Q3. Its up 0.24, from 1.41 in 2017Q2. It is positive, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Renaissance Techs Limited Liability reported 1.44 million shares stake. Quantbot Limited Partnership invested in 0.01% or 4,754 shares. Amalgamated Bankshares has invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). Orbimed Advisors Limited Com holds 1.34% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 10.00M shares. Tiaa Cref Investment Mgmt Ltd Limited Liability Company invested in 0% or 272,375 shares. Bancshares Of New York Mellon reported 681,419 shares. Quantitative Systematic Strategies Limited Liability has invested 0.04% in Immunomedics, Inc. (NASDAQ:IMMU). Credit Suisse Ag holds 129,313 shares. 911,926 are owned by Geode Capital Management Ltd Limited Liability Company. Weiss Multi accumulated 100,000 shares. Susquehanna Grp Inc Llp reported 88,459 shares. Deutsche Commercial Bank Ag accumulated 1.39M shares. Tower Research Capital Ltd Limited Liability Company (Trc) has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). 1.95 million were reported by Ghost Tree Cap Ltd Liability. Rhumbline Advisers invested in 0% or 124,726 shares.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on February, 8. They expect $-0.10 earnings per share, up 37.50% or $0.06 from last year’s $-0.16 per share. After $-0.16 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -37.50% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts